Abstract 585: Elevated levels of CD24 in head and neck squamous carcinoma cells: A potential marker for unfavorable cisplatin response
Conclusion: Our work thus far, indicates that higher expression of CD24 in head and neck tumors result in a cisplatin resistant population that may well be the cause of unfavorable response to cisplatin treatment. Overall, CD24 has the potential to be a valuable predictor of response to cisplatin in HNSCC patients as well as a therapeutic target.Citation Format: Vishnu Modur. Elevated levels of CD24 in head and neck squamous carcinoma cells: A potential marker for unfavorable cisplatin response. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 585. doi:10.1158/1538-7445.AM2015-585
Source: Cancer Research - Category: Cancer & Oncology Authors: Modur, V. Tags: Clinical Research (Excluding Clinical Trials) Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | Head and Neck Cancer | HNSCC | Laryngeal Cancer | Stem Cell Therapy | Stem Cells | Study